Tekla Capital Management’s Medicines Co MDCO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-120,670
| Closed | -$10.3M | – | 227 |
|
|
2019
Q4 | $10.3M | Sell |
120,670
-15,005
| -11% | -$1M | 0.39% | 58 |
|
|
2019
Q3 | $6.78M | Sell |
135,675
-142,417
| -51% | -$5.68M | 0.3% | 67 |
|
|
2019
Q2 | $10.1M | Sell |
278,092
-15,300
| -5% | -$499K | 0.41% | 56 |
|
|
2019
Q1 | $8.2M | Sell |
293,392
-135,600
| -32% | -$3.2M | 0.33% | 64 |
|
|
2018
Q4 | $8.21M | Buy |
428,992
+263,151
| +159% | +$6.12M | 0.35% | 62 |
|
|
2018
Q3 | $4.96M | Sell |
165,841
-72,900
| -31% | -$2.75M | 0.18% | 93 |
|
|
2018
Q2 | $8.76M | Sell |
238,741
-39,650
| -14% | -$1.29M | 0.33% | 70 |
|
|
2018
Q1 | $9.17M | Buy |
+278,391
| New | +$8.7M | 0.36% | 62 |
|
|
2017
Q1 | – | Sell |
-771,638
| Closed | -$26.2M | – | 148 |
|
|
2016
Q4 | $26.2M | Buy |
771,638
+207,200
| +37% | +$7.35M | 1.12% | 25 |
|
|
2016
Q3 | $21.3M | Sell |
564,438
-139,800
| -20% | -$5.27M | 0.82% | 30 |
|
|
2016
Q2 | $23.7M | Buy |
704,238
+139,800
| +25% | +$4.93M | 0.97% | 27 |
|
|
2016
Q1 | $17.9M | Buy |
564,438
+162,468
| +40% | +$5.31M | 0.76% | 32 |
|
|
2015
Q4 | $15M | Sell |
401,970
-222,330
| -36% | -$8.4M | 0.54% | 37 |
|
|
2015
Q3 | $23.7M | Buy |
+624,300
| New | +$21.9M | 0.85% | 25 |
|
Other funds holding MDCO
Tekla Capital Management's MDCO Position: Q1 2020 in Review
Tekla Capital Management sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 120,670 shares — an estimated $10.3M sold.
Tekla Capital Management first reported a position in MDCO in Q3 2015 and held it in 14 quarters. The position peaked at $26.2M in Q4 2016. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.
- Tekla Capital Management reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
- Tekla Capital Management sold 120,670 Medicines Co shares in Q1 2020, an estimated $10.3M.
- Tekla Capital Management first reported a position in Medicines Co in Q3 2015 and held it in 14 quarters.
- Tekla Capital Management's Medicines Co position peaked at $26.2M in Q4 2016.
- 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.
Based on Tekla Capital Management's 13F filing for Q1 2020, filed 14 May 2020.